Therapeutic Advances of Rare ALK Fusions in Non-Small Cell Lung Cancer

doi:10.3390/curroncol29100618

Article

Therapeutic Advances of Rare ALK Fusions in Non-Small Cell Lung Cancer

16 Oct 2022

Abstract excerpt

Non-small cell lung cancer (NSCLC) accounts for approximately 85% of all lung cancer cases and is the leading cause of cancer-related death. Despite advances in chemotherapy and immunotherapy, the prognosis for advanced patients remains poor. The discovery of oncogenic driver mutations, such as anaplastic lymphoma kinase (ALK) mutations, means that a subset of patients has opportunities for targeted therapy. With...

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

discussions

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.